Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Target

Dividend growth stocks are superb wealth-creation vehicles. These two blue chips are among the best in the category.

2 Magnificent Dividend Growth Stocks to Buy Now

Abbott on Monday announced it has received FDA clearance for two new CGMs that will be available without a prescription. A CGM is a small sensor that pokes through the skin and tracks a person's glucose levels in real-time.

FDA approves two new Abbott over-the-counter continuous glucose monitors

Abbott said on Monday that the U.S. Food and Drug Administration has cleared its two continuous glucose monitoring systems for over-the-counter use.

US FDA clears Abbott's continuous glucose monitors for over-the-counter use

Abbott Laboratories gained U.S. clearance Monday for a pair of new CGMs. The news could push Abbott stock closer to a breakout.

Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom

Abbott's consumer biowearable, Lingo™, is designed for general consumers who are looking to improve their overall health and wellness Libre Rio™ is designed for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications Both products are based on FreeStyle Libre® sensing technology, the world's most widely used1 continuous glucose monitoring (CGM) systems, pioneered by Abbott and used by about 6 million people globally2 ABBOTT PARK, Ill., June 10, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by about 6 million people globally2.

Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems

Emerson Electric

Johnson & Johnson

From 1930 to 2023, 70% of dividend stocks in the top two quintiles outperformed the S&P 500 during recessions. Dividends have contributed 40% of the stock market gain since 1930, increasing with rising inflation.

The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash

In the closing of the recent trading day, Abbott (ABT) stood at $103.23, denoting a -0.19% change from the preceding trading day.

Abbott (ABT) Stock Dips While Market Gains: Key Facts

Deere & Company

Diamondback Energy

Medtronic

Old Dominion Freight Line

Recent data indicates a heightened risk of stagflation, with slowing economic growth and persistent inflation. This poses challenges for the economy and portfolios, but also presents opportunities to buy beaten-down stocks with strong pricing power and growth potential. My focus remains on resilient dividend growth stocks and sectors like energy and healthcare, which are well-positioned for these conditions.

The 2 Most Important Charts I Want (Dividend) Investors To See

Wall Street analysts have a 'strong buy' rating on ABT stock, with 12 out of 24 analysts giving it this rating in the last 90 days. We agree with such bullish sentiment. Despite some risks, ABT stock has the potential to outperform the overall market by a large margin.

Abbott Laboratories: Why I Agree With Wall Street On This One

Cadrenal Therapeutics Inc

Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, has the potential to improve the time in therapeutic range a factor correlated in the ARIES-HM3 trial with better patient outcomes PONTE VEDRA, Fla. , June 3, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today highlighted a groundbreaking presentation at the International Society for Heart & Lung Transplantation (ISHLT) 44th Annual Meeting & Scientific Sessions.

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

The latest trading day saw Abbott (ABT) settling at $101.74, representing a +1% change from its previous close.

Abbott (ABT) Rises As Market Takes a Dip: Key Facts

GE HealthCare Technologies Inc

UnitedHealth Group

Healthcare stocks to buy are booming in the U.S. due to the nation's aging population. Spending on healthcare in the U.S. now totals $4.4 trillion, or $13,493 per person, each year — more than any other country on earth.

Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for May 2024

Comcast

Home Depot

Kinder Morgan

Kroger

Sempra Energy

Earlier, the Federal Reserve stood poised to cut the benchmark interest rate, which boded well for reliable dividend stocks. Essentially, Uncle Sam's high yields wouldn't compete with the passive income stemming from private enterprises.

Reliable Rewards: 7 Dividend Stocks to Count On in Any Market

Blackstone Group

Estee Lauder

The bull market continues; markets quickly dusted off the 5% correction in April and soared to new highs. With too much cash on the sidelines, every shallow correction has become a buying opportunity.

Blue-Chip Bonanza: 3 Stocks to Ride the Market's Coattails to Riches

Abbott's (ABT) share recovery in the Nutrition business buoys optimism.

Here's Why You Should Hold on to Abbott (ABT) Stock for Now

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?

CME Group

L3Harris

Viper Energy Partners LP

I see a shift from growth to value stocks due to persistent inflation and interest rate challenges. Based on my thesis, I present four fantastic dividend growth stocks with great business models, attractive valuations, and favorable dividend profiles. These companies offer solid dividends, growth potential, and balanced risk/reward profiles. They are well-positioned to outperform the S&P 500, providing both value and security in a shifting market.

Paradigm Shift! 4 Of My Favorite Dividend Stocks To Buy Right Now

Abbott Laboratories is one of the smaller holdings in my portfolio, but that won't be the case for much longer. Strength throughout the base business powered the company's sales higher in the first quarter. ABT's interest coverage ratio approached 25 in the most recent quarter, which supports an AA- credit rating from S&P.

Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock

Fund managers have historically pivoted to top dividend stocks in low-interest-rate environments. With the Fed poised to start cutting interest rates within the next eight to 12 months, these two blue chip dividend stocks could be compelling buys.

These Dividend Stocks Are an Investor's Best Friend

Bank of America

Honeywell

JPMorgan Chase & Co

Coca-Cola

Merck

If you want your portfolio to pay you cash like clockwork, it's time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.

JP Morgan Has 5 Blue Chip Passive Income Stocks as Top Picks for May

Indian drugmaker Abbott India reported a 24% rise in fourth-quarter profit on Thursday, as strong sales outpaced the impact of government pricing caps on certain medicines.

Drugmaker Abbott India posts Q4 profit rise on higher sales

Pfizer

Often overlooked, especially in times of AI revolution, the healthcare market is always a safe bet for investors, as it is a multiple trillion, highly innovative industry with no drawbacks like lack of demand per se.

Here's why you should buy these 3 stocks and hold them forever

Johnson & Johnson is a steady portfolio stalwart. Abbott Labs has exciting growth opportunities ahead.

Got $1,000? 3 Dividend Stocks to Buy and Hold Forever

IRVINE, Calif.--(BUSINESS WIRE)--Appriss Retail, a leading provider of data and analytics solutions designed to reduce retail losses, decrease returns, and provide a more seamless consumer experience, announced today that Dean Abbott has joined the team as the company's chief data scientist. The news comes amid Appriss Retail's recent solution advancements and global expansion. Abbott will work with Appriss Retail's global retail customers to optimize data and analytical processes in his new ro.

Appriss Retail Names Industry Veteran and Innovator Dean Abbott Chief Data Scientist

Healthcare stocks certainly haven't set the world on fire lately. The S&P Health Care Index is up 3% so far in 2024 compared to an 8% gain in the benchmark S&P 500.

News for Abbott Labs Stock (ABT)